Cookies help us deliver our services. By using our services, you agree to our use of cookies. More information

Difference between revisions of "CH Basel Uteng M"

From Bioblast
(Created page with "{{MiPNetLab |address=Novartis Pharma AG, Werk Klybeck Postfach, CH-4002 Basel Switzerland |city=Basel |country=Switzerland |MiPNetLab=Riebel V |info=IOC36, IOC39 }}")
ย 
ย 
(6 intermediate revisions by 4 users not shown)
Line 1: Line 1:
{{MiPNetLab
{{O2k-Network Lab
|address=Novartis Pharma AG, Werk Klybeck
|institution=Novartis Pharma AG, Werk Klybeck
ย 
|area code=4002
Postfach, CH-4002 Basel
ย 
Switzerland
|city=Basel
|city=Basel
|country=Switzerland
|country=Switzerland
|MiPNetLab=Riebel V
|Contact=Uteng Marianne,
|info=IOC36, IOC39
|MiPNetLab=Riebel Virginie
|Team previous=Dong Min
|Status=O2k 2006-
|info=[[MiPNet12.14 IOC39|IOC39]], [[MiPNet11.06 IOC36|IOC36]]
}}
}}
* Previously CH_Muttenz_Dong M

Latest revision as of 11:22, 16 May 2019

                



CH Basel Uteng M

Oroboros O2k-Network

O2k-Network
O2k-Network Lab Novartis Pharma AG, Werk Klybeck
Address , 4002
City Basel
State/Prov
Country Switzerland
Weblink
Contact Uteng Marianne
Team Riebel Virginie
Team previous Dong Min
Status O2k 2006-
Oroboros Events IOC39, IOC36
Topics


O2k-Publications

 PublishedReference
Brecht 2016 Toxicol In Vitro2016Brecht K, Riebel V, Couttet P, Paech F, Wolf A, Chibout SD, Pognan F, Krรคhenbรผhl S, Uteng M (2016) Mechanistic insights into selective killing of OXPHOS-dependent cancer cells by arctigenin. Toxicol In Vitro 40:55-65.

O2k-Abstracts

update please

  • Previously CH_Muttenz_Dong M